NovoCure (NVCR) Net Cash Flow Growth (1y) (2015 - 2026)
NovoCure (NVCR) Net Cash Flow Growth (1y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | -53.07% |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | 17.60% |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | 10.50% |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | -283.58% |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | -564.44% |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | -31.84% |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | -394.13% |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | 76.43% |
| 10 | NovoCure | 1.97 Bn | 1.53 Bn | 142.48 Mn | -71.91% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -71.91% |
| Mar 31, 2026 | 83.91% |
| Dec 31, 2025 | -949.62% |
| Sep 30, 2025 | 831.48% |
| Jun 30, 2025 | 107.77% |
| Mar 31, 2025 | -117.17% |
| Dec 31, 2024 | -126.76% |
| Sep 30, 2024 | 2,435.48% |
| Jun 30, 2024 | -891.50% |
| Mar 31, 2024 | 203.62% |
| Dec 31, 2023 | 166.89% |
| Sep 30, 2023 | 99.28% |
| Jun 30, 2023 | -116.53% |
| Mar 31, 2023 | 494.10% |
| Dec 31, 2022 | 73.32% |
| Sep 30, 2022 | -137.44% |
| Jun 30, 2022 | 409.22% |
| Mar 31, 2022 | -122.47% |
| Dec 31, 2021 | -4,596.91% |
| Sep 30, 2021 | 775.84% |